NasdaqGM - Delayed Quote USD

MannKind Corporation (MNKD)

4.1800 +0.1000 (+2.45%)
At close: 4:00 PM EDT
4.1800 0.00 (0.00%)
After hours: 4:04 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Michael E. Castagna Pharm.D. CEO & Director 1.53M -- 1977
Mr. Steven B. Binder Chief Financial Officer 854.28k -- 1963
Ms. Lauren M. Sabella Executive VP & COO 1.39M -- 1961
Dr. David B. Thomson J.D., Ph.D. Executive VP, General Counsel & Secretary 862.23k -- 1967
Dr. Stuart A. Tross Ph.D. Executive VP and Chief People & Workplace Officer 739.45k -- 1967
Mr. Sanjay Singh M.B.A. Executive Vice President of Technical Operations 364.53k -- 1966
Ms. Rosabel Realica Alinaya VP of Investor Relations & Treasury 402.26k -- 1961
Mr. John F. Bedard Senior Vice President of Worldwide Regulatory Affairs -- -- 1950
Mr. James Patrick McCauley Jr., J.D., M.B.A. Chief Commercial Officer 614.06k -- 1966
Dr. Burkhard Blank M.D. Executive VP of Research & Development and Chief Medical Officer -- -- 1955

MannKind Corporation

1 Casper Street
Danbury, CT 06810
United States
818 661 5000 https://www.mannkindcorp.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
411

Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Corporate Governance

MannKind Corporation’s ISS Governance QualityScore as of April 1, 2024 is 3. The pillar scores are Audit: 6; Board: 3; Shareholder Rights: 4; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
MannKind Corporation Earnings Call

Related Tickers

UTHR United Therapeutics Corporation
237.93
+0.42%
 
LQDA Liquidia Corporation
13.29
-3.77%
 
ACAD ACADIA Pharmaceuticals Inc.
16.82
-1.46%
 
CLDX Celldex Therapeutics, Inc.
37.98
-1.43%
 
IOVA Iovance Biotherapeutics, Inc.
11.31
-3.50%
 
KNSA Kiniksa Pharmaceuticals, Ltd.
16.91
+0.18%
 
RIGL Rigel Pharmaceuticals, Inc.
1.0800
+2.86%
 
NKTR Nektar Therapeutics
1.2400
-6.06%
 
PBYI Puma Biotechnology, Inc.
5.01
+0.40%
 
IDYA IDEAYA Biosciences, Inc.
37.13
-1.30%